Last reviewed · How we verify
NCT06988462
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
NA trial testing Bottarga in Prediabetes in 20 participants. Currently enrolling.
25 August 2026
Quick facts
| Lead sponsor | Cambridge Health Alliance |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 17 October 2025 |
| Primary completion | 25 August 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Bottarga
- Comparator
Conditions studied
- Prediabetes — all drugs for Prediabetes →
- Diabetes — all drugs for Diabetes →
- High Cholesterol/Hyperlipidemia — all drugs for High Cholesterol/Hyperlipidemia →
- Obesity & Overweight — all drugs for Obesity & Overweight →
Sponsor
Cambridge Health Alliance — full company profile →
Who can join
Adults 18 to 60, any sex, with Prediabetes or Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes. Before initiating the crossover randomized controlled trial (RCT), the investigators will conduct a preliminary dose-testing study in five adults with at least one metabolic abnormality. Participants will undergo clinical assessments before and after the dietary intervention to evaluate changes in metabolic health markers. Following this phase, the investigators will proceed with a randomized, controlled crossover trial involving 20 eligible adult participants. This main study phase will compare the metabolic effects of daily bottarga supplementation with those of a calorically matched dairy product over an 8-week intervention period, with a 2-week washout period between interventions. The investigators anticipate that bottarga supplementation will improve lipid profiles, inflammation markers, and insulin resistance, thereby supporting the potential use of sustainable blue foods as part of a healthy diet.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06988462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prediabetes
Currently open trials in the same condition.
- NCT07529366 — Pharmacist-Led Continuous Glucose Monitoring for Prediabetes · recruiting
- NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
- NCT07478263 — Behavioral Approach for Latinas Addressing Nutrition, Cravings, and Eating Patterns to Prevent Type 2 Diabetes · NA · recruiting
- NCT07491653 — Fiber mHealth Intervention for Prediabetes · NA · recruiting
- NCT07372729 — Smartwatch-based Intervention for Cardiovascular Health (SWITCH) · NA · recruiting
Other Cambridge Health Alliance trials
Trials by the same sponsor.
- NCT06419595 — Screening and Support for Youth (SASY) · NA · not yet recruiting
- NCT07513220 — The Effectiveness and Acceptability of Formal Versus Informal Mindful Self-Compassion for Adolescents · NA · not yet recruiting
- NCT06564948 — Treatment for Individuals Interacting with the Criminal Justice System · NA · recruiting
- NCT06765122 — Program for Alleviating and Reducing Trauma and Stress for Intimate Partner Violence · NA · completed
- NCT06515925 — Our Whole Lives Gemini: Virtual Integrative Medical Group Visits for Managing Chronic Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06988462 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cambridge Health Alliance
- Last refreshed: 19 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06988462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing